Incidence of molecular mutations in AML subgroups AML-NOS, AML-MRC with MDS-related cytogenetics and/or MDS/MPN history, and AML-MLD-sole
| Mutation (no. of patients analyzed*) . | Patients with mutation, n (%) . | AML-NOS n = 233 (%) . | AML-MRC due to cytogenetics and/or MDS or MDS/MPN history n = 85 (%) . | AML-MLD-sole n = 90 (%) . | P . |
|---|---|---|---|---|---|
| NPM1 (n = 397) | 203 (51.1) | 144 (62.3) | 10 (12.3) | 49 (57.6) | < .001 |
| FLT3-ITD (n = 398) | 89 (22.4) | 68 (29.4) | 6 (7.4) | 15 (17.4) | < .001 |
| NRAS (n = 187) | 24 (12.8) | 8 (8.7) | 8 (16.0) | 8 (17.8) | NS |
| MLL-PTD (n = 399) | 24 (6.0) | 10 (4.3) | 6 (7.4) | 8 (9.3) | NS |
| CEBPA (n = 225) | 17 (7.6) | 9 (7.1) | 3 (6.7) | 5 (9.3) | NS |
| Mutation (no. of patients analyzed*) . | Patients with mutation, n (%) . | AML-NOS n = 233 (%) . | AML-MRC due to cytogenetics and/or MDS or MDS/MPN history n = 85 (%) . | AML-MLD-sole n = 90 (%) . | P . |
|---|---|---|---|---|---|
| NPM1 (n = 397) | 203 (51.1) | 144 (62.3) | 10 (12.3) | 49 (57.6) | < .001 |
| FLT3-ITD (n = 398) | 89 (22.4) | 68 (29.4) | 6 (7.4) | 15 (17.4) | < .001 |
| NRAS (n = 187) | 24 (12.8) | 8 (8.7) | 8 (16.0) | 8 (17.8) | NS |
| MLL-PTD (n = 399) | 24 (6.0) | 10 (4.3) | 6 (7.4) | 8 (9.3) | NS |
| CEBPA (n = 225) | 17 (7.6) | 9 (7.1) | 3 (6.7) | 5 (9.3) | NS |
The P values result from the comparison of the frequency of molecular markers between the 3 cohorts (patients with AML-NOS, AML-MRC because of cytogenetics, and MDS history, or AML-MLD-sole).
NS indicates not significant.
From our cohort of 408 patients.